Natural Products Foundation Met FTC to Discuss Misleading Ads
In a December 2011 meeting, the NPF requested FTC action on 22 misleading advertisements.
The Natural Products Foundation (NPF) tracks down and monitors misleading dietary supplement ads through its Truth in Advertising program. In 2011, the organization mailed 85 warning letters to misleading dietary supplement advertisers and most of them ultimately put their ads into compliance.
The NPF now says that its legal advisory council chairman, Marc Ullman, met with the FTC’s Richard Cleland on December 19, 2011, to discuss 22 non-compliant advertisers. All advertisers failed to put their ad claims into compliance after being contacted by the NPF Truth in Advertising program and now the NPF has requested disciplinary action from FTC.
“Anytime that a senior representative of the FTC is willing to take time out of their incredibly busy schedule to review the work that we are doing within the [Truth in Advertising] program, we are getting the kind of feedback that underscores how important self-regulation is in today’s regulatory climate,” said Ullman.
For more information about the Truth in Advertising program and how to keep your marketing claims in check, visit the link above.
The NPF legal advisory council is headed by Marc Ullman (Ullman, Sharpio &Ullman; New York City), Jackie Kuler (Gronek & Associates; Chicago), and Nicholas Licato (Nexgen Pharma; Irvine, CA).
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
